The mainstay of leprosy treatment until 1984 was dapsone monotherapy. Although it resulted in reduction of leprosy prevalence globally and the leprosy trends started plateauing, deformities and complications continued to occur and dapsone resistance was documented [1] . Subsequently, from 1985 onwards, multidrug therapy (MDT) was the key public health intervention that helped in reducing the global leprosy burden substantially [1] . Initially, the duration of MDT was recommended as two years or until smear negativity for multibacillary (MB) leprosy. For paucibacillary (PB) leprosy, a two-drug combination of rifampicin and dapsone for six months and rifampicin once a month were recommended. Subsequently, over the years, based on the collective experience, the WHO through its two expert committees and a study group modified the treatment regimen. The key modifications were two years of fixed period for MB (1988) and later reduced duration for MB to 12 months (1998) . Further, the WHO recommended single-dose regimen (rifampicin, ofloxacin and minocycline) for single-lesion PB patients [1] . During the implementation of MDT, national vertical programmes focussed on early case detection and treatment of all leprosy patients with MDT [2] . Most countries were successful in achieving leprosy elimination by the end of first decade of the current century, and vertical leprosy programmes were integrated into the primary health care services [3] , [4] . Such integration demanded further simplification of patient management practices including follow up. The WHO strategy for 2011-2015 focuses on sustaining the initiatives to reduce burden of leprosy in all the endemic communities [5] .
A simplified approach to leprosy diagnosis and treatment is deemed important for the sustainability of leprosy control services under programmatic conditions. In this context, MB-MDT regimen given for six-month duration was proposed as uniform MDT (U-MDT) regimen for all types of leprosy. Ji and Saunderson [6] expressed concerns regarding this approach and the trial design not having a control group. These have been addressed in our earlier publication [7] . The goal of chemotherapy should be to shorten and optimize treatment regimen to achieve desired outcomes with minimum/acceptable side effects. For reducing the duration of MB-MDT, supportive evidence was available from experimental and clinical trials. Experimental studies suggested that MDT for 2-3 months was capable of killing almost all viable bacilli in the mouse footpad model [8] , [9] . Further, the rifampicin-resistant mutants in an untreated lepromatous patient were likely to be eliminated by three months' daily treatment with dapsoneclofazimine combination and by that time rifampicin with three monthly doses would have killed over 99.9 per cent of the viable Mycobacterium leprae [8] . This was further confirmed by a clinical trial, in which loss of infectivity of M. leprae after only one month of the WHO MB-MDT or with a single dose of rifampicin was documented [10] . It is, therefore, reasonable to believe that patients would respond to six months' MB-MDT, but a smaller number of them may relapse, who could continue on MDT without any risk of drug resistance. Second issue of importance is the addition of clofazimine for PB-MDT. Evidence from a randomized controlled clinical trial of PB-MDT plus daily clofazimine versus routine PB-MDT suggested that the proportion with persisting active skin patches was considerably lower in the clofazimine arm (7.5%) compared to PB-MDT arm (16%), and in the six month post-PB-MDT follow up, clofazimine group demonstrated better response than the control group (80 vs. 30%) [11] . Further, clofazimine could be potentially beneficial against type 2 reactions in leprosy patients [12] . In addition, the combination of three drugs may possibly reduce the chance of drug resistance. A controlled trial with control group could be justified only for a small fraction of highly bacteriologically positive patients (about 2% of newly diagnosed leprosy patients), who could be at risk of possible inadequate treatment and increased risk of relapse. However, based on the principle of equivalence, one would require a substantially large sample size for such a trial, which is practically not feasible. In view of the discontinuation of skin smears in the programmes [1] , it will not be possible to identify such high-risk patients. U-MDT trial was undertaken as programme implementation research with phase IV clinical trial perspective. National Institute of Epidemiology (NIE) of the Indian Council of Medical Research (ICMR), in Chennai, India, coordinated the U-MDT trial. The primary objective of this trial was to assess treatment response to U-MDT in terms of relapse rate not exceeding a maximum cumulative level of five per cent at the end of five years. The secondary objectives were to assess acceptability, safety and compliance to the U-MDT regimen. Here, we present the final results of the trial.
Material & Methods
It was a single-arm open-field trial. The trial was initiated in October 2003 and the final five years' follow up at the last site (Rohtas in Bihar, India) was completed in January 2014.
Sample size:
Considering the five year maximum relapse rate of five per cent as acceptable limit (Poisson distribution; P o =5%; P a =3%) with the power of 90 per cent, type 1 error of 5 per cent (one-tailed test) and loss to follow up of 30 per cent in field situations, the required sample size was 2223 which was rounded off to 2500 for each type of leprosy.
Study settings: During 2003 During -2004 , the trial was initiated at six sites -four districts in India (Pune, Kanpur, Tiruvannamalai and Villupuram) and two provinces in P. R. China (Guizhou and Yunnan). Two sites from India -Gaya and Rohtas districts were subsequently included in 2005 and 2007, respectively. The trial was conducted at the district level by leprosy control programme officers in three sites in India (Tiruvannamalai and Villupuram in Tamil Nadu and Pune in Maharashtra). At Kanpur in Uttar Pradesh, the trial was conducted by the National JALMA Institute for Leprosy and Other Mycobacterial Diseases (ICMR), Agra. In two sites of Bihar (Gaya and Rohtas), Damien Foundation India Trust, Chennai, conducted the trial in collaboration with the leprosy programme. In PR China, the trial was conducted as part of national leprosy control programme.
Study participants:
Newly detected and treatment-naive leprosy patients were recruited in the trial. Patients with access to the clinic and available to receive U-MDT under supervision and willing for long-term follow up were included after obtaining written informed consent. Patients who had only neuritic manifestations or who had been previously treated for leprosy, were excluded.
in the presence of the investigators for six months. For adults, the regimen consisted of supervised pulse of 600 mg rifampicin, 300 mg clofazimine and 100 mg dapsone every four weeks along with daily-unsupervised course of 50 mg clofazimine and 100 mg dapsone. The supervised dosage for children aged 10-14 years was 450 mg rifampicin, 150 mg clofazimine and 50 mg dapsone every four weeks and 50 mg clofazimine every alternate day and 50 mg dapsone daily. For children <10 yr, the dose (mg) was adjusted to body weight (kg) as follows: rifampicin 10-20 mg/kg, clofazimine 1-2 mg/kg and dapsone 1-2 mg/kg of the body weight. All the drugs were supplied by the WHO with a special labelling of U-MDT for adult and child blister packs separately for the entire duration of the trial.
Data collection:
The investigators of all the sites assessed every new leprosy patient for suitability for inclusion in the study as per the protocol. Patients who decided not to join the study or found ineligible were given regular MDT as per the national leprosy programme guidelines in India or P. R. China. During the treatment period patients were interviewed and carefully examined for adverse drug reactions (ADRs), leprosy reactions and neuritis at the time of their monthly visit for receiving the supervised dose of treatment. Subsequently, occurrence of clinical events such as relapse, reactions, disability and neuritis and other events such as migrations and deaths was recorded during the yearly follow up visits after completion of treatment. Patients developing new lesions, pain in the nerves, joint pains, fever and any other complaint were requested to report and were examined and treated as early as possible. The NIE, Chennai, monitored the trial for its duration and ensured adherence to the trial protocol at the trial sites. In addition, reporting forms were collected, scrutinized and entered in the trial database at NIE. Discrepancies found during scrutiny were clarified with the study sites. Further, quality checks were conducted through on-site supervision visits and periodic monitoring throughout the study period. Operational definitions used in the trial are given elsewhere [7] .
The study protocol was approved by the Institutional Human Ethics Committees of the participating organizations. All the participants in the study provided written informed consent administered in their local languages. (Clinical Trials Registry of India: 2012/05/002696).
Data analysis:
Baseline characteristics of the study participants at all the study sites were analyzed and frequencies were estimated. Per protocol analysis was done and person years (PY) for study participants were calculated from the time of completion of treatment to the observation of primary outcome (relapse) or from the time of recruitment till the time of lost to follow up due to suspected ADR (during treatment period) or non-clinical events or completion of five years post-treatment. Those with relapse, suspected ADR or any of the non-clinical events were right censored and thereafter they ceased to contribute to the person-time of observation. For those who had temporarily migrated and then joined the study later, the maximum PYs contributed by them, i.e. from enrolment to each of those follow up time-points, were calculated. Event rates per 100 PY were also calculated. The rates were compared using Chisquare test. Further, cumulative risk [risk=1-e (−rate× period) ] of relapse for five years was computed. We used SPSS18.0 (SPSS Inc., Chicago, IL, USA) and Open Epi [13] were used for data analysis. Figure B ]. Forty eight patients could not be enrolled for various reasons including ineligibility (n=34), duplication of records (n=7), other reasons (n=6) and declined to participate (n=1). Of these ineligible patients,19 had pure neuritic leprosy and were put on routine MDT. Of the total recruited, MB% ranged between 27 per cent (168 of 631) in Gaya and 67 per cent (111 of 166) in P. R. China (Tiruvannamalai: 46% of 520; Villupuram: 45% of 505; Pune: 34% of 812; Kanpur: 40% of 316; Rohtas: 33% of 439). Of the total enrolled, 3169 completed the prescribed treatment. Thirty participants (PB=21 and MB=9) completed the treatment beyond nine months after initiation, and hence, they were excluded from subsequent analysis. Table 2 ]. The relapse rate per 100 person years (PY) was 0.02 (total PY=8780) and the cumulative risk over five years was 0.11 per cent. One of the relapses occurred in the second year and the patient was put on routine MDT by the site investigator. The second relapse occurred in the third year [ Table 3 ] of follow up and was put on one more course of U-MDT. Both had their skin lesions 'improved' at the completion of the trial. During the study period, a total of 645 special events were reported among PB patients. Of these, 301 events resulted in lost to follow up due to clinical (n=10) or non-clinical events (n=291). The remaining 344 were events that did not lead to lost to follow up (clinical events=114 and temporary migrations=230) [ Table 2 ].
Results

During
At the end of five years post-treatment follow up, the death rate was 0.25 per 100 PY (n=24) among PB patients. Of these deaths, one was reportedly due to complications following leprosy reactions from Guizhou site in P. R. China. Seven deaths were due to injuries (suicide=2, snake bite=1 and motor vehicle accidents=4), followed by four cardiac problem-related deaths. Cause of death was unknown for four deaths.
Of the total PB patients recruited, 2.7 per cent (n=57) refused to continue in the study for various reasons. Majority of them were self-refusal for clinical examination during follow up (n=30). Twelve participants did not report any reason for discontinuation.
Among the lost to follow up, 27 were due to various reasons such as shifting outside the study area (n=20) and being found ineligible during the treatment period (wrong diagnosis or pregnancy). P. R. China site removed four patients from the trial since they were either put on routine MDT by investigators (n=3) or as opted by the patient (n=1).
The clinical events leading to lost to follow up included eight suspected ADR (total PY=1009; rate=0.79). As per the WHO/TDR guidelines (http://www.who.int/tdr/publications/documents/investigator. pdf?ua=1) and based on available clinical notes, one of the ADR was classified as 'probably'(exfoliative dermatitis with jaundice) and seven as 'possibly' related to the drug. Of the reported clinical events, rate of occurrence (per 100 PY) of new lesions on account of reactions was 0.24 (n=23) and that of neuritis was 0.39 (n=37). Of the total neuritis, 24 were reported independently and 13 were reported along with type 1 reaction. Rate of occurrence of type 1 reaction was 0.54 (n=51). Type 2 reaction was 0.03 (n=3) per 100 PY from two PB patients ( first year=2 and fourth year=1) who also had nerve lesions at the time of enrolment.
Status of skin lesions during follow up:
Of the total PB patients, 97 per cent patients had either inactive or improved skin lesions at the time of completion of treatment and 0.5 per cent had static lesions at the end of fifth year of post-U-MDT [ Table 4 ]. 
Secondary outcomes: All of the MB patients accepted U-
MDT regimen in all the sites. There were no complaints about clofazimine. The skin pigmentation due to clofazimine was reported to be of short duration and acceptable to the enrolled patients with MB leprosy. Of the total 1298 who accepted U-MDT, 94 per cent (n=1220) completed the regimen and 52 per cent (n=675) consumed doses within six months.
In all, 636 special events were reported among MB patients. Of these, 223 were clinical (n=20) or non-clinical (n=203) leading to lost to follow up. The remaining 413 events (clinical=296 and temporary migrations=117) did not result in lost to follow up [ Table 2 ]. Fifty MB patients died during the follow up period (rate: 0.88 per 100 PY). Of these, nine each were due to respiratory failure and liver diseases and eight deaths were due to cardiac problems. Seven deaths were reportedly due to injuries (suicide=4; drowning=2; homicide=1). Ten MB patients died due to various causes. Cause of death was unknown for seven patients.
Of the 30 patients who refused to continue in the study for various reasons, 12 patients refused clinical examination during follow up, and for five of them, the regimen was changed and nine did not report any reason for discontinuation. Three patients refused because they were not interested in continuing in the study and one patient refused on account of stigma.
Among the lost to follow up reported under 'others' events, 20 were due to various reasons such as shifting outside the study area (n=13). P. R. China site removed seven patients from the trial since five of them were put on routine MDT [either by the investigators (n=4) or as opted by patient (n=1)] and two patients received additional dose of clofazimine.
Of the clinical events leading to lost to follow up, 16 were due to suspected ADRs (total PY=605; rate=2.64 per 100 PY). Of these, seven had dapsone-induced exfoliative dermatitis and were classified as 'probably' and rest as 'possibly' related to the drug. Of the reported clinical events, rate of occurrence (per 100 PY) of new lesions on account of reactions was 1.34 (n=74) and that of neuritis was 1.37 (n=78). Of the neuritis, 43 were reported independently and 29 were reported along with type 1 and six with type 2 reactions. Rate of occurrence of type 1 reaction was 2.01 (n=114) and that of type 2 reaction was 0.49 (n=28) per 100 PY [ Table 2 ]. Type 2 reactions (28 events from 24 patients) occurred during treatment and throughout the follow up. Table 4 ].
Status of skin lesions during follow up:
Discussion :
Our observation of low level of relapse was consistent with the findings from the most recent randomized controlled trial from Brazil that compared U-MDT with regular MDT (0.09 per 100 PY; two relapses during 2139 PY) [14] , [15] . Rate documented in our trial was much lower than the reported relapse rates from programmatic settings and other field trials [16] , [17] , [18] , [19] , [20] , [21] [maximum rates (per 100 PY): 0.65 in PB and 2.04 in MB]. Based on information available from leprosy programmes, the WHO reports frequency of relapse per year as 0.1 per cent for PB and 0.06 per cent for MB [22] . According to India's leprosy programme, the country as a whole reported 433 clinical relapses for the year 2013-2014 with one larger province reporting the maximum (n=236) [21] .
In the present study, almost all the new patients in the eight centres (98.6%) were enrolled and 94 per cent of them completed U-MDT treatment in nine months indicating good acceptability and compliance. The profile of study participants represented the actual scenario of new leprosy cases at the community level. Among these patients, low relapse rates were observed after completion of U-MDT. Thus, in this trial, apart from the question of extent of relapses in PB and MB patients, it was possible to consider overall effectiveness of this treatment regimen under routine programmatic conditions. Since this study was taken up for patient treatment, case detection became more proactive from the point of view of recruitment. This would explain a lower level of MB proportion among the new cases in this study.
With regard to safety of the regimen, the addition of clofazimine could potentially offer clinical and cost benefits. In terms of clinical benefits, clofazimine possibly reduces incidence of neuritis in PB and type 2 reactions in MB. The present study was not designed to test these beneficial effects. However, the observed incidence rates of neuritis and type 2 reactions and cumulative risk of neuritis (1.94% and 6.63% in PB and MB, respectively) and type 2 reactions (0.16% and 2.43% in PB and MB, respectively) were lower than those reported in the literature. For instance, the overall incidence of neuritis reported ranges between 6.1 and 34 per cent [ India's national leprosy programme reported 12,901 episodes of reactions/neuritis episodes for 2013-2014 for the entire country [18] . In the programmatic context, addition of clofazimine may theoretically add to the cost to treat leprosy. However, such costs will be offset by reduction in morbidity among PB patients and hence reduced cost of management of such morbidities. Reduced duration of regimen for MB will further halve the cost of regimen. Thus U-MDT regimen will actually reduce the cost of leprosy treatment.
Advantages and implications for leprosy programmes
U-MDT trial was essentially a programmatic implementation research. Hence, it is worth considering the findings in the context of its implications for programmes. Nearly all new treatment naive patients from the study areas were included. Proportion of MB was lower than PB (38 vs. 62%) and MB patients had nerve involvement. We expect this to be generally representative of the real-life situation in the programme. We tried to keep implementation of the U-MDT as per the programme routine. However, the case detection had been proactive and the follow up of the patients was more rigorous. It is expected that if U-MDT is implemented in the programme situation with appropriate sensitization of patients and providers, it will help in effectively reducing leprosy prevalence at the district/regional levels as well.
In the national leprosy programme (India), skin smear and ICMR Bulletin ○ Jan -Feb 2018 skin biopsies are not performed. In the absence of such testing, it is essential to consider how much could be the probable misclassification in the present study. PB-MB grouping is employed primarily on the assumption that the protective immunity is inversely correlated with the number of lesions [35] . In programmatic conditions, it was thus possible that some of the leprosy patients would have been misclassified as PB or MB [36] . However, the extent of such misclassification in the present study seems to be minimal. For instance, a low rate of type 2 reactions among PB (rate=0.03; risk=0.16%) was observed as compared to 0.49 per 100 PY among MB patients (risk=2.43%, P<0.001).
Two study sites carried out skin smear test as part of their implementing agency's or country's policy and practice although skin smear examination was not required as per common protocol. P. R. China sites performed skin smear examination and documented rapid fall in bacteriological index with almost 95 per cent MB patients becoming smear negative at the end of five years of follow up [37] , [38] . This information further supports the applicability of U-MDT in the programme.
Finally, there is a need to consider implications of trial findings on the follow up strategy while adopting U-MDT in programmes. All the suspected ADRs were reported within a maximum of three months, and all the relapses occurred within first three years after treatment completion. Further, it was noted that the occurrence of type 2 reactions was continuing during post-treatment follow up. Hence, the primary health care physicians will require necessary clinical expertise to recognize and manage such clinical events. There is a need to educate and counsel patients to be alert about any such event and report immediately to the primary health care providers.
Only a small number of patients in PB and MB had static lesions at the end of five years post-U-MDT. Since relapses occurred within first three years after U-MDT, a carefully crafted strategy for periodic follow up algorithm during the first three years after MDT might help in picking up relapse patients relatively early. In 2013-2014, India's leprosy programme confirmed that a sizeable number of suspected relapses at the primary health care level (n=486) were referred and confirmed at the district hospital level (n=433) [21] . Hence, the national leprosy programmes could implement such a strategy of identification, referral and management at appropriate levels.
Limitations and biases
Our study had few limitations and biases. Key limitation was that of inability to meet the sample size requirements for MB. Due to overall reduction in prevalence, adequate number of patients could not be enrolled in the given geographic areas of the study sites. Further, the sample size was calculated for an expected relapse rate of three per cent (P a ) in the study groups, i.e., two per cent less than an assumed level of five per cent (P o ). At the end of the trial, we observed relapse of <1 per cent. The power to detect this two per cent difference (i.e., between 3 and 1%) was 100 per cent for PB and 99.9 per cent for MB group. Therefore, even with the recruited number of participants, we had closer to 100 per cent power to support our conclusions of efficacy of the six-month U-MDT regimen to prevent relapses in PB and MB types of leprosy patients.
In terms of biases, two types of selection biases might be considered. The study sites were purposively selected on the basis of ability to recruit patients and to offer better services and follow up. Further, as only those patients who were willing, were enrolled, there could be some level of selection bias at the level of participants. However, in most of our field sites, almost all the patients opted for U-MDT, and hence, such selection bias would be minimal. Further, due to the active nature of follow up from the investigators and the coordinating centre, it is possible that research bias might have contributed to the higher treatment completion rates than the reported figures in programme settings. The study, funded by Indian Council of Medical Research (ICMR), New Delhi, was carried out from 2015-2017 in Karnataka, Tamil Nadu and undivided Andhra Pradesh. It found that the gap in accessing healthcare between women from vulnerable group and those who are financially better off has drastically decreased since the launch of JSY. D.C. Nanjunda, Associate Professor and Deputy Director, CSSEIP, and his group has shown that increase in the use of JSY has reduced the long prevalent disparities in maternal healthcare delivery. Also, OBC, Dalit, Adivasi and Muslim women have shown much interest to utilise the scheme. Delivery at houses is found to be around 1.2% even today in Karnataka. This is mainly because of traditional health behaviour and poor transport facilities in rural areas, the centre said in its report.
The study has shown the drop in maternal morbidity and rise in deliveries in government hospitals. However, required antenatal care and postnatal care needs much improvement in all the three states, says Dr. Nanjunda. In most cases, pre-and post-natal care will depend on the decision and attitudes of the family, according to the study.
The beneficiaries were largely from various segments of the society having different socio-economic backgrounds, a handout by the centre said here.
The Hindu| January 19, 2018
Tobacco use is taking a high toll on the health of Indians
According to the World Health Organization, tobacco use kills more than seven million people every year, globally. With nearly 270 million adults, above the age of 15 years, using tobacco in some form or the other in India, the death toll due to tobacco use in the country is more than one million every year. While globally, cigarette smoking is the biggest killer, for India and most of the neighboring countries from the Region smokeless tobacco (SLT) form is the larger part of the tobacco use burden. According to the recent Global Adult Tobacco Survey India Report, 2017, one in every five Indian is hooked to SLT. Among men, two most commonly used tobacco products are SLT i.e. khaini (8.5 crore) and gutkha (5.1 crore). Amongst women, the three most commonly used are SLT i.e. betel quit (2 crore), oral application (2 crore) and khaini (1.9 crore).
SLT causes several health problems for its users. SLT can cause oral and other cancers, in addition to other mouth diseases and heart disease. In India, the use of SLT remains the dominant cause of tobacco-attributable diseases, including oral cancer. SLT not only causes adverse health effects but is also responsible for a huge economic burden. According to the Ministry of Health and Family Welfare report, on the health cost of tobacco use, males contributed 91% of the total economic burden of Rs 1,04,500 crore in the year 2011. However, the contribution from females was much higher at 29 per cent for SLT. If one considers only the direct medical cost, female share in costs attributable to SLT increased substantially to 66 per cent. In addition, the average expenditure on purchase of SLT has doubled to Rs 12.8/-in 2017 compared to 2010. With almost 20 crore SLT users, this amount is a huge dent in household expenditure, exposing poor and vulnerable families to further poverty. This expenditure on SLT use which otherwise could be used in essentials like education, food and milk for children.
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SLT use is also responsible for creating a huge amount of solid and non-bio-degradable waste. Besides, tobacco cultivation impacts the environment in many ways, e.g. tobacco growing leads to depletion of nutrients from the soil and leads to soil erosion, deforestation, disturbance in patterns of bio-diversity including continuous ecological damage due to deforestation. Disposal of tobacco-related waste and litter is another grave environmental burden due to tobacco use. Invoking the principle of 'Polluter pays' the High Court of Rajasthan directed the tobacco manufacturers in the state against the use of plastic packaging. The Supreme Court of India upheld the order and as a result, the Ministry of Environment and Forest amended Plastic Waste (Management and Handling) Rules, 2011 to prohibit the use of plastic materials in sachets for storing, packing or selling gutkha, tobacco and pan masala.
Taking further steps to prevent the use of SLT, the Indian government issued a notification under the Food Safety and Standards law stating that food products must not contain any substance which may be injurious to health. The regulation prohibited tobacco and nicotine from being used as ingredients in food items. This led a series of ban on sale and manufacture of gutkha across the country with Madhya Pradesh being the first state to initiate the ban.
The Union Ministry of Health and Family Welfare suggested state governments to take further stronger measures to curb SLT use in the country by issuing a prohibitory order against manufacture and sale of any kind of SLT products. The state of Assam became the first state to issue a blanket ban on all SLT products in February 2014. Several states, including Bihar, Maharashtra and Mizoram have since then issued stronger regulations concerning ban on SLT products.
Evidence suggests that any tobacco control regulation, unless comprehensive, does not yield the intended public health objective. To make sure that the intended objectives of gutkha ban and the proposed SLT ban are achieved, all stakeholders must work together for a comprehensive ban on manufacture and sale of smokeless tobacco in the country. Provision for accessible and affordable cessation services for all SLT users who plan to quit is the first step towards meeting this objective.
SLT use mixed with areca nut is a common practice in India and stated in the beginning, betel quid and gutkha the two most commonly used forms of SLT have areca nut as a common ingredient. Areca nut itself is classified as having class one carcinogen properties i.e. cancer-causing properties, besides responsible for other adverse health effects. The combination of tobacco and areca nut put their users, mostly women from the poor and vulnerable sections of the society, to a completely preventable risk of disease and death.
We the people of this country should enter into another final combat, this time against the use of tobacco, and set ourselves free from the clutches of this ill-habit.
The author is Director, ICMR -National Institute of Cancer Prevention and Research DNA:| January 25. 2018
High prevalence of vitamin D deficiency in elderly
It leads to weakening of bones and hypertension. Deficiency of vitamin D in the elderly may be more commonplace than thought, suggests a recentlypublished study by researchers from the National Institute of Nutrition (NIN).
In a study published in the journal Annals of Human Biology earlier this month, a team of scientists concluded that prevalence of vitamin D deficiency was high among elderly population in Hyderabad. For the study, researchers randomly selected 298 people aged over 60 and collected blood samples to asses concentrations of 25-hydroxy vitamin D in the serum. Though it is not clearly established why vitamin D deficiency is highly prevalent in India, Dr. Shankar offered a few explanations including reduced exposure to sunlight, diet and cooking preferences.
While mentioning their findings, NIN researchers pointed out that the odds of vitamin D deficiency in an elderly person with clinical hypertension was twice that of a same-age individual without hypertension. This suggests that vitamin D deficiency should be investigated in elderly with hypertension.
The Hindu: January 28, 2018
Can't Ask Doctors to Compensate Over Failed IVF Treatments: National Consumer Commission
National Consumer Commission, doctors and hospitals cannot be made to pay compensation in case the In Vitro Fertilization (IVF) treatments do not succeed. The article adds that the Commission emphasized that if the doctors have treated patients in accordance with the well-established norms under the ICMR guidelines, they cannot be faulted.
News18.com | January 4, 2018
ICMR soon to begin research on 'Viral hepatitis in India'
The article informs that ICMR will soon begin research on Viral Hepatitis in India. It states that ICMR's initiative is significant as viral hepatitis is increasingly being recognized as a public health problem, having epidemic proportions that cause 1.34 million deaths each year. The article adds that there is a paucity of nationally representative data to establish accurate disease burden of viral hepatitis.
Pharmabiz.com | January 8, 2018
STD alarm: Drugs fail to control gonorrhea
The article states that scientists of National AIDS Research Institute, Pune, along with by Osmania and Gandhi Medical College researchers have found multidrug resistant strains of sexually transmitted disease, gonorrhea. Informing that the emergence of Neisseria gonorrhoeae is a big public health challenge in controlling sexually transmitted diseases, the article adds that at least 124 strains of gonorrhea causative were isolated in past few years in Delhi, Pune, Mumbai, Secunderabad and Hyderabad to determine antimicrobial susceptibility.
The Times of India | January 8, 2018 
ICMR News
Newborns Don't Need Hepatitis B Vaccine Immediately After Birth, Can Wait For 6 Months, Says ICMR Study
The article states that an ICMR funded study has shown that newborns are protected at birth by natural antibodies to Hepatitis-B, and lends support to the government's pragmatic approach to vaccinate babies born at home starting at six weeks instead of birth. Dr. Puliyel however has cautioned that more studies are needed to confirm this before changes in immunization practice can be recommended.
Outlook India | January 13, 2018
Govt. The article informs of an ongoing research project which was given to SS Hospital and Research Centre, Kankarbagh by ICMR in 2015. In the project, researchers from Patna conducted studies on Swiss albino mice to determine whether genes get affected by the toxic metalloid and pesticide. Proof of gene expression abnormalities causing cancer and infertility due to arsenic and endosulfan (widely used pesticide) poisoning was found in Gangetic and stagnant water in Bihar. It also states that the samples tested revealed that it caused cancer and infertility. The article adds that the final report with definite results about the change in gene expression shall be submitted to ICMR by June 2018.
Deccan Chronicle | February 12, 2018
Centre's study to uncover 'village of science'
A detailed study shall be conducted in Dhadkai, 'The Village of Silence' in Jammu & Kashmir to discover reasons why most babies are born deaf and dumb in the remote hamlet. It adds that a study published in the latest edition of the Indian Journal of Medical Research (IJMR) had pointed out "considerable genetic heterogeneity in the causation of hearing loss in Dhadkai." It quotes Geetika Yadav, researcher from ICMR, stating that population-based genetic counselling may be the key to prevent the same in future.
The Pioneer | February 14, 2018
'ICMR institutes' merger to improve resource
allocation, boost capacities'
The article is an interview of Dr. Sanjay Mehendale, Additional Director General, ICMR where he states the need of restructuring ICMR institutes. Dr. Mehendale highlighted that the merger of institutes will enable ICMR institutes to share resources, reduce expenditure and provide holistic public health research. He also added that this decision was based on the recommendations of Performance Evaluation Committee constituted by the Ministry of Health and Family Welfare which has also recommended to increase the research funding of ICMR, strengthen technical capacity to undertake health research by attracting new talent, modernise extramural research platforms, undertake world class research training, increase the age of superannuation to the same as those of central medical institutes, and to nurture multi-sector collaboration.
The Indian Express | February 17, 2018
Researchers to study epilepsy & marriage to standardize support
The article states that researchers from Indian Council of Medical Research (ICMR) will be conducting detailed research on epilepsy. The article also highlights that ICMR recently convened a meeting of neurologists with expertise in epilepsy management, neuropsychologists and social scientists to identify research gaps and pose research questions in relation with marriage and the pre-existing occurrence of epilepsy.
The Times of India | February 18, 2018
Govt moves to protect medical records of terminally ill patients
The article reports of the draft policy on data processing and disclosure that aims to protect patient confidentiality and privacy in disease registries developed by National Centre for Disease Informatics and Research (NCDIR), Bengaluru, ICMR. The policy will help safeguard registries for cancer, stroke and cardiovascular diseases which are thought to be vulnerable to data breaches. The article quotes Dr. Ravi Mehrotra, Director, National Institute of Cancer Prevention and Research stating that the policy is needed as in the near future, there may be a statutory mandate for hospitals and other sources to supply data on non-communicable diseases to the ICMR-NCDIR.
Livemint | February 20, 2018
THSTI, ICMR sign MoU for building research ecosystem
The article informs on signing of a Memorandum of Understanding (MoU) between ICMR and Translational Health Science and Technology Institute (THSTI), an autonomous institute of the Department of Biotechnology, Ministry of Science and Technology. The main objective of this association is to build the basic, clinical, translational and implementation research ecosystem in India.
Biospectrum | February 20, 2018
Focus on eliminating kala azar, leprosy, TB & malaria
The article informs on the directives issued by Anupriya Patel, Minister of State for Health & Family Welfare in a high-level meeting to review the activities and achievements of the Department of Health Research (DHR) and the ICMR. The Minister has directed ICMR to prioritize the elimination of kala azar, leprosy, tuberculosis and malaria and asserted that ICMR should work on a mission mode to achieve the target by 2018-end. She also stressed on the need to increase Viral Research Diagnostics Laboratories (VRDL) in states, including in Uttar Pradesh, and directed officials to set up more Multi-Disciplinary Research Units in the northeastern states.
India Today | February 23, 2018
Commercial launch likely for male contraceptive
The article informs of decades-old male contraceptive invention that has undergone several trials that may soon see a commercial launch, after the country's regulators have formally seen that it is reversible. It quotes Dr. R.S. Sharma, Head of Reproductive Health, Indian Council of Medical Research (ICMR) stating that the injectable molecule's efficiency is beyond question and it has also shown to have been reversible in primates. He added that besides the reversible studies, a Phase III B clinical trial would be held, after which it is likely that the molecule could be commercially launched within the next five years.
The Hindu | February 26, 2018
Congo fever virus widely prevalent in the country's livestock, finds NIV
The article states that National Institute of Virology (NIV) has confirmed wide prevalence of an extremely virulent tick-borne virus in the country's livestock that has killed 31 people since 2011, when it was first identified in humans in India. It quotes Dr. DT Mourya, Director, NIV stating that from the blood samples of 5,636 domestic animals picked up randomly across the country, 354 animals were found carrying the virus in their blood. He added that active surveillance may reveal even more prevalence of the virus in our livestock, which is a serious concern. NIV scientists have developed a diagnostic kit (CCHF IgG Elisa) for tracking the virus transmission in domestic animals.
The Times of India | February 27, 2018
The following meetings of various technical committees/Groups of the Council were held in January-February 2018
17.
Technical Advisory Committee (TAC) meeting NCD-II 2/2/2018 18.
The meeting of expert group on fellowship 2/2/2018 19.
Signing 
